If I only had taken wagers like that on this board over the past few yrs I wouldn't even care about InMed's share price because I'd be sitting cushier than Mr. Adams is today.
Also, don't make assumptions on subject matter you don't understand. If you did your own research you'd understand the specific limitations of a bacterial approach for this process. The differences between prokaryotic vs eukaryotic cells are essential to understand when looking at cannabinoid biosynthesis.
"Its yeast fermentation production platform, initially developed for cannabigerol ("CBG") and cannabidiol ("CBD"), has shown impressive success and Willow expects to be the FIRST company to biosynthetically produce material amounts of cannabinoids."
News 
Market Data 
Discover 
AI
